Ado-Trastuzumab Emtansine
Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination.
Year introduced: 2020 (2010)
PubMed search builder options
Subheadings:
Tree Number(s): D02.540.505.495.500, D04.345.295.500.500, D12.776.124.486.485.114.224.060.875.500, D12.776.124.790.651.114.224.060.875.500, D12.776.377.715.548.114.224.200.875.500
MeSH Unique ID: D000080044
Registry Number: SE2KH7T06F
Entry Terms:
- Ado Trastuzumab Emtansine
- Trastuzumab Emtansine
- huN901-DM1
- huN901DM1
- huN901 DM1
- Kadcyla
- Trastuzumab-DM1 Conjugate
- Trastuzumab DM1 Conjugate
- Trastuzumab-DM1
- Trastuzumab DM1
Pharmacologic Action: